NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART,
DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION
FOR
IMMEDIATE RELEASE
8 February
2024
RECOMMENDED CASH
OFFER
by
IOPS
BUYER INC.
(a
wholly-owned subsidiary of Wellspring Worldwide Inc.)
for
SOPHEON
PLC
Results of Court Meeting
and General Meeting held on 8 February 2024
On 22 December 2023, the boards of
Sopheon Plc ("Sopheon") and
IOps Buyer Inc. ("Bidco"),
a wholly-owned subsidiary of Wellspring Worldwide Inc.
("Wellspring"), which is a
portfolio company of funds managed and/or advised by Resurgens,
announced that they had reached agreement on the terms of a
recommended all cash offer pursuant to which Bidco would acquire
the entire issued and to be issued share capital of Sopheon (the
"Acquisition"). It is
intended that the Acquisition will be effected by means of a
Court-sanctioned scheme of arrangement of Sopheon under Part 26 of
the Companies Act 2006 (the "Scheme").
A circular in relation to the Scheme
("Scheme Document"),
setting out, amongst other things, notices of the Court Meeting and
General Meeting was published by Sopheon and made available to
Sopheon Shareholders on 16 January 2024.
Capitalised terms used in this
Announcement shall, unless otherwise defined, have the same
meanings as set out in the Scheme Document. All references in this
Announcement to times are to London, United Kingdom time unless
otherwise stated.
At the Court Meeting, as more
particularly described below, a majority in number of Scheme
Shareholders present and voting (and entitled to vote), either in
person or by proxy at the Court Meeting, representing not less than
75 per cent. in nominal value of the Scheme Shares held by such
Scheme Shareholders, present and voting at the Court Meeting (or
any adjournment of the Court Meeting), voted in favour of the
resolution to approve the Scheme.
At the General Meeting, as more
particularly described below, the requisite majority of Sopheon
Shareholders voted to pass the special resolution proposed at the
General Meeting to approve the implementation of the Scheme. The
Sopheon Shareholders also voted to pass the special resolution to
adopt new articles of association of Sopheon and, subject to the
Scheme becoming Effective, re-register Sopheon as a private limited
company (among other things).
Details of the resolutions passed
are set out in the notices of the Court Meeting and General Meeting
in Parts VIII and IX (respectively) of the Scheme Document, which
is available on Sopheon's website
at https://www.sopheon.com/investors.
Accordingly, the Scheme was
approved.
The total number of Sopheon Shares
in issue at the Voting Record Time was 10,706,805. No Sopheon
Shares were held in treasury. Consequently, the total voting rights
in Sopheon at the Voting Record Time were 10,706,805.
Voting results of the Court Meeting
The results of the poll at the Court
Meeting are set out in the table below. Each Scheme Shareholder
present in person or by proxy was entitled to one vote for each
Scheme Share held at the Voting Record Time. The percentages are
rounded to two decimal places.
Results of Court
Meeting
|
FOR
|
AGAINST
|
TOTAL
|
Number of Scheme Shares
voted
|
8,529,402
|
119,418
|
8,648,820
|
Percentage of Scheme Shares voted by
those Scheme Shares represented at the Court Meeting
|
98.62%
|
1.38%
|
100%
|
Number of Scheme Shareholders who
voted[1]
|
63
|
5
|
65[2]
|
Percentage of Scheme Shareholders who
voted out of those Scheme Shareholders present and voting at the
Court Meeting
|
96.92%
|
7.69%
|
100%[3]
|
Number of Scheme Shares voted as a
percentage of the issued ordinary share capital eligible to be
voted at the Court Meeting
|
79.66%
|
1.12%
|
80.78%
|
Voting results of the General Meeting
The results of the poll at the
General Meeting are set out in the table below. Each Scheme
Shareholder present in person or by proxy was entitled to one vote
for each Scheme Share held at the Voting Record Time. The
percentages are rounded to two decimal places.
|
FOR
|
AGAINST
|
TOTAL
|
WITHHELD[4]
|
Special Resolution
|
Number of votes
|
Percentage of votes
|
Number of votes
|
Percentage of votes
|
Number of votes
|
Percentage of votes
|
Number of votes
|
Percentage of votes
|
Implementation
of the Scheme, including amendments
to Sopheon's articles of association.
|
8,585,620
|
97.56%
|
214,605
|
2.44%
|
8,800,225
|
100%
|
0
|
0%
|
Conditions
The outcome of the Court Meeting and
the General Meeting means that Conditions 2(a)(i) and 2(a)(ii) (as
set out in Part A of Part 3 of the Scheme Document) have been
satisfied. The Scheme remains subject to the satisfaction or (where
applicable) waiver of the remaining Conditions (as set out in Part
3 of the Scheme Document) that have not yet been satisfied,
including the Court sanctioning of the Scheme at the Court Hearing
which is expected to take place on 16 February 2024 at The Royal
Courts of Justice. It is currently expected that the Effective Date
will be 20 February 2024.
Expected Timetable of Principal Events
The Scheme Document contains an
expected timetable of principal events in relation to the Scheme,
which is also set out in the Appendix to this
Announcement.
All dates and times are based on
Sopheon's, Resurgens', Wellspring's and Bidco's current
expectations and are subject to change. If any of the dates and/or
times in this expected timetable change, the revised dates and/or
times will be notified to Sopheon Shareholders by announcement
through a Regulatory Information Service and by posting notice of
these dates on the following website:
https://www.sopheon.com/investors.
Enquiries:
Sopheon
|
via Cavendish
|
Andy Michuda, Executive
Chairman
|
|
Greg Coticchia, Chief Executive
Officer
|
|
Arif Karimjee, Chief Financial
Officer
|
|
|
|
Cavendish (Nominated Adviser and Broker to the
Company)
|
+44 (0) 20 7220 0500
|
Henrik Persson
|
|
Carl Holmes
Abigail Kelly
|
|
George Dollemore
|
|
|
|
Resurgens, Wellspring and Bidco
|
via Raymond James
|
Adi Filipovic
|
|
Fred Sturgis
|
|
Danny Carpenter
|
|
|
|
Raymond James (Financial Adviser to Resurgens, Wellspring and
Bidco)
|
+44 (0) 20 3798 5700
|
Junya Iwamoto
|
|
Felix Beck
|
|
King & Spalding International
LLP are retained as legal advisers to Resurgens, Wellspring and
Bidco.
Squire Patton Boggs (UK) LLP are
retained as legal adviser to Sopheon.
Important Notices
Cavendish, which is authorised and regulated in the United
Kingdom by the FCA, is acting as financial adviser to Sopheon and
no one else in connection with the matters described in this
Announcement and will not be responsible to anyone other than
Sopheon for providing the protections offered to clients of
Cavendish or for providing advice in connection with any matter
referred to in this Announcement. Neither Cavendish nor any of its
affiliates (nor their respective directors, officers, employees or
agents) owes or accepts any duty, liability or responsibility
whatsoever (whether direct or indirect, whether in contract, in
tort, under statute or otherwise) to any person who is not a client
of Cavendish in connection with this Announcement, any statement
contained herein, the Scheme or otherwise. No representation or
warranty, express or implied, is made by Cavendish as to the
contents of this Announcement.
Raymond James, which is authorised and regulated in the United
Kingdom by the FCA, is acting as financial adviser to Resurgens,
Wellspring and Bidco and no-one else in connection with the matters
described in this Announcement and will not be responsible to
anyone other than Resurgens, Wellspring or Bidco for providing the
protections afforded to clients of Raymond James nor for providing
advice in connection with the matters referred to herein. Neither
Raymond James nor any of its affiliates owes or accepts any duty,
liability or responsibility whatsoever (whether direct or indirect,
whether in contract, in tort, under statute or otherwise) to any
person who is not a client of Raymond James in connection with this
Announcement, any statement contained herein, the Acquisition or
otherwise.
Further Information
This Announcement is for information purposes only and is not
intended to and does not constitute, or form any part of, an offer
to sell or subscribe for or any invitation to purchase or subscribe
for any securities or the solicitation of any vote or approval in
any jurisdiction pursuant to the Acquisition or otherwise. The
Acquisition will be made solely through and on the terms set out in
the Scheme Document (or, in the event that the Acquisition is to be
implemented by means of a Takeover Offer, the offer document) and
the accompanying Forms of Proxy, which will contain the full terms
and conditions of the Acquisition, including details of how to vote
in respect of the Acquisition. Any approval, decision or other
response to the Acquisition should be made only on the basis of the
information in the Scheme Document. Scheme Shareholders are
strongly advised to read the formal documentation in relation to
the Acquisition once it has been despatched.
The statements contained in this Announcement are made as at
the date of this Announcement, unless some other time is specified
in relation to them, and service of this Announcement shall not
give rise to any implication that there has been no change in the
facts set forth in this Announcement since such
date.
Overseas Shareholders
This Announcement has been prepared for the purpose of
complying with English law, the AIM Rules and the Code and the
information disclosed may not be the same as that which would have
been disclosed if this Announcement had been prepared in accordance
with the laws of jurisdictions outside the United
Kingdom.
The laws of the relevant jurisdictions may affect the
availability of the Acquisition to persons who are not resident in
the United Kingdom. Persons who are not resident in the United
Kingdom, or who are subject to laws of any jurisdiction other than
the United Kingdom, should inform themselves about, and observe any
applicable requirements. Any person (including, without limitation,
nominees, trustees and custodians) who would, or otherwise intends
to, forward this Announcement, the Scheme Document or any
accompanying document to any jurisdiction outside the United
Kingdom should refrain from doing so and seek appropriate
professional advice before taking any action. In particular, the
ability of persons who are not resident in the United Kingdom to
vote their Sopheon Shares at the Court Meeting or the General
Meeting, or to execute and deliver Forms of Proxy appointing
another to vote their Sopheon Shares in respect of the Court
Meeting or the General Meeting on their behalf, may be affected by
the laws of the relevant jurisdiction in which they are
located.
Any failure to comply with the applicable legal or regulatory
requirements may constitute a violation of the laws and/or
regulations of any such jurisdiction. To the fullest extent
permitted by applicable law, the companies and persons involved in
the Acquisition disclaim any responsibility and liability for the
violation of such restrictions by any person.
The Acquisition will not be made, directly or indirectly, in
or into or by use of the mails or any other means or
instrumentality (including, without limitation, telephonic or
electronic) of interstate or foreign commerce of, or any facility
of a national, state or other securities exchange of, a Restricted
Jurisdiction, and the Acquisition will not be capable of acceptance
by any such use, means, instrumentality or facility or from within
a Restricted Jurisdiction. Accordingly, copies of this Announcement
and formal documentation relating to the Acquisition are not being,
and must not be, directly or indirectly, mailed or otherwise
forwarded or distributed in, into or from a Restricted Jurisdiction
and persons receiving this Announcement (including custodians,
nominees and trustees) must not distribute or send it into or from
a Restricted Jurisdiction. In the event that the Acquisition is
implemented by way of a Takeover Offer and extended into the US,
Bidco will do so in satisfaction of the procedural and filing
requirements of US securities laws at that time, to the extent
applicable thereto. The Acquisition relates to the shares of a
company incorporated in England and it is proposed to be made by
means of a scheme of arrangement provided for under English law.
The Scheme will relate to the shares of a UK company that is a
"foreign private issuer" as defined under Rule 3b-4 under the US
Exchange Act. A transaction effected by means of a scheme of
arrangement is not subject to any shareholder vote, proxy
solicitation and tender offer rules under the US Exchange
Act.
Accordingly, the Scheme is subject to the disclosure
requirements and practices applicable in the UK to schemes of
arrangement, which differ from the disclosure requirements and
practices of US shareholder vote, proxy solicitation or tender
offer rules. Financial information included in the relevant
documentation will have been prepared in accordance with accounting
standards applicable in the UK and may not be comparable to the
financial information of, or the accounting standards applicable
to, US companies. However, if Bidco were to elect to implement the
Acquisition by means of a Takeover Offer, such Takeover Offer shall
be made in compliance with all applicable laws and regulations,
including section 14(e) of the US Exchange Act and Regulation 14E
thereunder, if applicable. Such Takeover Offer would be made in the
US by Bidco and no one else. In addition to any such Takeover
Offer, Bidco, certain affiliated companies and the nominees or
brokers (acting as agents) may make certain purchases of, or
arrangements to purchase, shares in Sopheon outside such Takeover
Offer during the period in which such Takeover Offer would remain
open for acceptance. If such purchases or arrangements to purchase
are made they would be made outside the United States in compliance
with applicable law, including the US Exchange Act. It may be
difficult for a US-based investor to enforce his or her rights and
any claim he or she may have arising under US securities laws,
since the Scheme relates to the shares of a company located in the
UK, and some or all of its officers and directors may be residents
of non-US jurisdictions. A US-based investor may not be able to sue
a company located in the UK, or its officers or directors, in a
foreign court for alleged violations of US securities laws, and it
may be difficult to compel a foreign company and its affiliates to
subject themselves to a US court's judgment.
Forward-looking statements
This Announcement, oral statements made regarding the
Acquisition, and other information published by Sopheon, Bidco,
Wellspring and Resurgens may contain certain "forward-looking
statements" with respect to Sopheon, Bidco, Wellspring and
Resurgens. These forward-looking statements can be identified by
the fact that they do not relate only to historical or current
facts. Forward-looking statements often use words such as
"anticipate", "target", "expect", "estimate", "intend", "plan",
"goal", "believe", "will", "may", "should", "would", "could" or
other words or terms of similar meaning or the negative thereof.
Forward-looking statements include statements relating to, for
example, the following: (i) future capital expenditures, expenses,
revenues, earnings, synergies, economic performance, indebtedness,
financial condition, dividend policy, losses and future prospects;
(ii) business and management strategies of Resurgens, Wellspring
and/or Bidco and the expansion and growth of Sopheon and potential
synergies resulting from the Acquisition; and (iii) the effects of
government regulation on the business of Sopheon.
These forward-looking statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results, performance or developments to differ materially from
those expressed in or implied by such forward-looking statements.
These forward-looking statements are based on numerous assumptions
regarding present and future strategies and environments. None of
Resurgens, Wellspring, Bidco or Sopheon, nor any of their
respective associates, directors, officers, employees or advisers,
provides any representation, assurance or guarantee that the
occurrence of the events expressed or implied in any
forward-looking statements in this Announcement will actually
occur. You are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date hereof.
All subsequent oral or written forward-looking statements
attributable to Resurgens, Wellspring, Bidco or Sopheon or any
person acting on their behalf are expressly qualified in their
entirety by the cautionary statement above. Should one or more of
these risks or uncertainties materialise, or should underlying
assumptions prove incorrect, actual results may vary materially
from those described in this Announcement. None of Resurgens,
Wellspring, Bidco or Sopheon assume any obligation to update
publicly or revise forward-looking or other statements contained in
this Announcement, whether as a result of new information, future
events or otherwise, except to the extent legally
required.
Publication on website
In
accordance with Rule 26.1 of the Code, a copy of this Announcement
will be made available (subject to certain restrictions relating to
persons resident in Restricted Jurisdictions), free of charge, on
Sopheon's website at www.sopheon.com/investors and on Bidco's website
at https://offer.wellspring.com/news by no later than 12:00 noon
on the Business Day following this Announcement. Neither the
contents of this website nor the content of any other website
accessible from hyperlinks on such websites is incorporated into,
or forms part of, this Announcement.
Requesting hard copies
In
accordance with Rule 30.3 of the Code, a person so entitled may
request a hard copy of this Announcement, free of charge, by
contacting Sopheon's registrar, Link Group on +44 (0)371 664 0321.
Calls are charged at the standard geographic rate and will vary by
provider. Calls outside the United Kingdom will be charged at the
applicable international rate. The helpline is open between 9:00
a.m. to 5:30 p.m., Monday to Friday excluding public holidays in
England and Wales. Please note that Link Group cannot provide
any financial, legal or tax advice and calls may be recorded and
monitored for security and training purposes.
For persons who receive a copy of this Announcement in
electronic form or via a website notification, a hard copy of this
Announcement will not be sent unless so requested. In accordance
with Rule 30.3 of the Code, a person so entitled may also request
that all future documents, announcements and information to be sent
to them in relation to the Acquisition should be in hard copy
form.
Disclosure requirements of the Code
Under Rule 8.3(a) of the Code, any person who is interested in
1% or more of any class of relevant securities of an offeree
company or of any securities exchange offeror (being any offeror
other than an offeror in respect of which it has been announced
that its offer is, or is likely to be, solely in cash) must make an
Opening Position Disclosure following the commencement of the offer
period and, if later, following the announcement in which any
securities exchange offeror is first identified. An Opening
Position Disclosure must contain details of the person's interests
and short positions in, and rights to subscribe for, any relevant
securities of each of (i) the offeree company and (ii) any
securities exchange offeror(s). An Opening Position Disclosure by a
person to whom Rule 8.3(a) applies must be made by no later than
3:30 p.m. (London time) on the 10th business day following the
commencement of the offer period and, if appropriate, by no later
than 3:30 p.m. (London time) on the 10th business day following the
announcement in which any securities exchange offeror is first
identified. Relevant persons who deal in the relevant securities of
the offeree company or of a securities exchange offeror prior to
the deadline for making an Opening Position Disclosure must instead
make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes,
interested in 1% or more of any class of relevant securities of the
offeree company or of any securities exchange offeror must make a
Dealing Disclosure if the person deals in any relevant securities
of the offeree company or of any securities exchange offeror. A
Dealing Disclosure must contain details of the dealing concerned
and of the person's interests and short positions in, and rights to
subscribe for, any relevant securities of each of (i) the offeree
company and (ii) any securities exchange offeror(s), save to the
extent that these details have previously been disclosed under Rule
8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies
must be made by no later than 3:30 p.m. (London time) on the
business day following the date of the relevant
dealing.
If
two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire or control an
interest in relevant securities of an offeree company or a
securities exchange offeror, they will be deemed to be a single
person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by the offeree
company and by any offeror and Dealing Disclosures must also be
made by the offeree company, by any offeror and by any persons
acting in concert with any of them (see Rules 8.1, 8.2 and
8.4).
Details of the offeree and offeror companies in respect of
whose relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table on
the Takeover Panel's website at www.thetakeoverpanel.org.uk,
including details of the number of relevant securities in issue,
when the offer period commenced and when any offeror was first
identified. You should contact the Panel's Market Surveillance Unit
on +44 (0)20 7638 0129 if you are in any doubt as to whether you
are required to make an Opening Position Disclosure or a Dealing
Disclosure.
Independent advice
If
you are in any doubt about the contents of this Announcement or the
action you should take, you are recommended to seek your own
independent financial advice immediately from your stockbroker,
bank manager, solicitor or independent financial adviser duly
authorised under FSMA if you are resident in the United Kingdom or,
if not, from another appropriately authorised independent financial
adviser.
EXPECTED TIMETABLE OF PRINCIPAL
EVENTS
Event
|
Expected time and/or
date
|
Date of the Scheme
Document
|
16 January
2024
|
Latest time for lodging Forms
of Proxy for:
|
- Court Meeting (BLUE
form)
|
10:00 a.m.
on 6 February 2024
|
- General Meeting (WHITE
form)
|
10:15 a.m.
on 6 February 2024
|
Voting Record Time
|
6:00 p.m.
on 6 February 2024
|
Court Meeting
|
10:00 a.m. on 8
February 2024
|
General Meeting
|
10:15 a.m. on 8 February
2024
|
The following dates are
indicative only and subject to change[5]
[6]
|
Court Hearing (to sanction the
Scheme)
|
16
February 2024
|
Last day of dealings in, and for
registration of transfers of, and disablement in CREST of, Sopheon
Shares
|
19
February 2024
|
Scheme Record Time
|
6:00 p.m.
on 19 February 2024
|
Dealings in Sopheon Shares on AIM
suspended
|
7:30 a.m.
on 20 February 2024
|
Effective Date of the Scheme
|
20
February 2024[7]
|
Cancellation of admission to trading
of Sopheon Shares
|
at 7:00
a.m. on 21 February 2024
|
Latest date for despatch of cheques
and crediting of CREST stock accounts for Acquisition consideration
due under the Scheme
|
within 14
days after the Effective Date
|
Long Stop Date
|
4 March
2024[8]
|